Subset analysis showed that patients with WT1 mutation and concomitant FLT3-ITD had a worse outcome in terms of CR rate, RFS, and OS, compared with patients with WT1-mutated AML without FLT3-ITD co-mutation. This evidence concerns the gene FLT3 and acute myeloid leukemia.